Evidence map›Paper›PMID 36941833›Full record

ArticleClinical case reports2023

The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature.

Abdulrahman Al-Abdulmalek, Reem Al-Suliman, Mohammad Abu-Tineh, Mostafa Ali, Mohamed A Yassin

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Abdulrahman Al-AbdulmalekDepartment of Internal Medicine Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0000-0002-9814-2925
Reem Al-SulimanDepartment of Medical Oncology National Center for Cancer Care and Research Doha Qatar.
Mohammad Abu-TinehDepartment of Medical Oncology National Center for Cancer Care and Research Doha Qatar.ORCID https://orcid.org/0000-0002-2984-0252
Mostafa AliDepartment of Radiology Hamad Medical Corporation Doha Qatar.
Mohamed A YassinDepartment of Medical Oncology National Center for Cancer Care and Research Doha Qatar.
National Center for Cancer Care and Research · QAHamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between chronic myelogenous leukemia (CML) and tuberous sclerosis (TS) is unusual and uncommon. Here, we report a 24-year-old woman diagnosed with TS and later identified with CML, as the second case reported with such coexistence, treated with Nilotinib. This article proposes a hypothesis to explain the association. Therefore, we propose Nilotinib for the treatment of patients with such coexisting diseases. Further studies are warranted to reveal the dynamics between these conditions.

Indexed as

CMLtuberous sclerosistyrosine kinase inhibitors

Identifiers

PMID36941833
PMCPMC10024035
OpenAlexW4327815233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.